CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing Polihexanide (PHMB) as a treatment for Acanthamoeba keratitis, a rare and painful eye infection. It aims to conduct rigorous clinical trials to ensure the drug's safety and effectiveness, ultimately seeking regulatory approval for its use in patients.
This project will undertake preclinical and clinical research of the Orphan Drug Polihexanide (PHMB).
The main objective is to provide a safe and effective drug for the treatment of the rare ocular disease Acanthamoeba keratitis (AK) tested according to international regulatory standards.
This debilitating infectious disease is caused by a free living protozoan which, in the absence of treatment, can have catastrophic consequences such as severe pain, visual loss and eye enucleation.
There ar…
UNIVERSITE DE ROUEN NORMANDIE
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Italy, ACI SANT ANTONIO CT
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Italy, POMEZIA (Roma)
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
MOORFIELDS EYE HOSPITAL NHS FOUNDATION TRUST
United Kingdom, London
Type: Research institute
Activity type: Research Organisations
SME: No
Netherlands, HOOFDDORP
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
